Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Medpace Holdings, Inc. $MEDP

Mitsubishi UFJ Trust & Banking Corp lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 46,133 shares of the company’s stock after selling 9,728 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Medpace were worth $25,911,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of MEDP. Quent Capital LLC bought a new position in Medpace during the 3rd quarter valued at about $25,000. Optiver Holding B.V. bought a new position in Medpace during the 3rd quarter valued at about $27,000. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. bought a new position in Medpace during the 4th quarter valued at about $30,000. Finally, Quarry LP bought a new position in Medpace during the 3rd quarter valued at about $35,000. Institutional investors own 77.98% of the company’s stock.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Analyst/valuation coverage highlights Q1 beat and reaffirmed guidance, supporting fundamentals and valuation recovery — this helps underpin recent buying interest. A Look At Medpace (MEDP) Valuation After Strong Q1 Results And Reaffirmed 2026 Revenue Guidance
• Neutral Sentiment: Coverage of the Q1 earnings call highlights key analyst questions investors should watch (cancellations, book‑to‑bill, margins, pipeline), useful for monitoring upcoming guidance and execution risk but not new company facts. The 5 most interesting analyst questions from Medpace’s Q1 earnings call
• Negative Sentiment: Multiple class actions have been filed alleging securities fraud tied to alleged understatement of cancellation rates and overstatement of book‑to‑bill; law firms are soliciting lead plaintiffs and alerting investors to deadlines — this raises legal, financial and reputational risk and can increase stock volatility and potential future liabilities. MEDP Investor Alert: Medpace Sued for Securities Fraud Amid Cancellation Rates
• Negative Sentiment: Several national plaintiff firms (Rosen, Glancy Prongay Wolke, Bronstein, Levi & Korsinsky, Faruqi, Pomerantz, Schall, Bleichmar Fonti & Auld and others) are actively recruiting class members and reminding investors of the June 8, 2026 lead‑plaintiff deadline — expect continued headlines and potential headline‑driven trading. ROSEN, A LEADING LAW FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MEDP
• Negative Sentiment: Investor alerts emphasize potential recoveries for purchasers between April 22, 2025 and February 9, 2026 — while recovery outcomes are uncertain, settlement risk and defense costs could weigh on longer‑term sentiment until resolved. Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is owned by company insiders.

Medpace Stock Up 1.0%

Shares of NASDAQ:MEDP opened at $413.59 on Thursday. The firm’s 50 day moving average price is $469.46 and its 200-day moving average price is $533.61. Medpace Holdings, Inc. has a twelve month low of $284.10 and a twelve month high of $628.92. The stock has a market capitalization of $11.81 billion, a PE ratio of 26.00, a price-to-earnings-growth ratio of 2.14 and a beta of 1.39.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the prior year, the business earned $3.67 EPS. The business’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Leerink Partners lowered their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th. BMO Capital Markets lowered their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and lowered their target price for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Finally, Barclays lowered their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and an average target price of $467.08.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.